On September 21, JD HEALTH rose 3.09% in regular trading, trading at HK$37.58 per share, with turnover of HK$88.50 million. The stock was buoyed by a dual catalyst of a newly announced strategic partnership and a landmark AI development in specialty medicine.

On the news front, BGI Genomics and JD HEALTH officially announced a strategic partnership at the JD Global Tech Explorers Conference, with BGI Genomics' full range of genetic testing products now available on the JD HEALTH platform. The two parties will leverage their respective strengths in genetic testing technology, health consumer ecosystems, and user services to jointly enhance product accessibility and service experience, accelerating precision health services into the consumer mainstream.

Simultaneously, JD HEALTH, in collaboration with Professor Shen Lin's team at Peking University Cancer Hospital, released the first domestic specialty AI model evaluation set for gastrointestinal oncology internal medicine. This benchmark fills an industry gap and marks a critical step in advancing medical AI from general capabilities into specialized clinical depth. The evaluation set has been integrated into JD HEALTH's MedWork AI physician workstation for real-world clinical applications.

Within the Internet and Direct Marketing Retail sector, BABA-W rose 1.92%, JD-SW rose 0.95%, and MEITUAN-W gained 1.09%, reflecting broadly positive sector sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)